What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2022.2152321
Abstract: ABSTRACT Introduction Psoriatic arthritis (PsA) is a chronic arthritis typically associated with cutaneous psoriasis (PsO). Its pathogenesis is connected to an innate and acquired immune response, as well as genetic risk alleles. The extent of… read more here.
Keywords: next biological; psoriatic arthritis; biological targeted; targeted synthetic ... See more keywords
Combination biologics or targeted synthetic disease-modifying anti-rheumatic drugs in the treatment of spondyloarthritis: a systematic literature review
Sign Up to like & getrecommendations! Published in 2024 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2024.2327589
Abstract: ABSTRACT Introduction The advent of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have transformed the management of immune-mediated rheumatic diseases, including spondylarthritis (SpA). However, the data about combining b/ts DMARDs in the treatment of… read more here.
Keywords: synthetic disease; treatment; combination; modifying anti ... See more keywords
Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database.
Sign Up to like & getrecommendations! Published in 2023 at "Modern rheumatology"
DOI: 10.1093/mr/road031
Abstract: OBJECTIVE We compared the incidence rates of hospitalized infections (HIs) between tocilizumab (TCZ) and other biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in adults aged ≥75 years with rheumatoid arthritis (RA). METHODS We used a Japanese claims… read more here.
Keywords: synthetic disease; risk; hospitalized infections; biological targeted ... See more keywords
Characterization of patients with rheumatoid arthritis not using biologic/targeted synthetic disease-modifying drugs despite insufficient disease control: Another difficult-to-treat RA.
Sign Up to like & getrecommendations! Published in 2025 at "Modern rheumatology"
DOI: 10.1093/mr/roaf037
Abstract: OBJECTIVES To understand the prevalence and characteristics of rheumatoid arthritis (RA) patients not using biologic/targeted synthetic disease-modifying drugs (b/tsDMARDs) despite insufficient disease control. METHODS The data from 3172 RA patients in the FRANK (Fukuoka RA… read more here.
Keywords: disease; rheumatology; rheumatoid arthritis; using biologic ... See more keywords
Short- and longer-term cancer risks with biologic and targeted synthetic disease modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab570
Abstract: OBJECTIVE To estimate the occurrence and relative risks of first ever incident non-cutaneous cancer overall and by 16 sites in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs), by time since treatment… read more here.
Keywords: clinical practice; targeted synthetic; treatment; rheumatology ... See more keywords
Comparative effects of biological and targeted synthetic DMARDs on incident chronic kidney disease in patients with rheumatoid arthritis.
Sign Up to like & getrecommendations! Published in 2024 at "Rheumatology"
DOI: 10.1093/rheumatology/keae603
Abstract: OBJECTIVES The impact of individual biological/targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARD) on kidney function in patients with rheumatoid arthritis (RA) remains unclear. This study aimed to determine the comparative effects of b/tsDMARDs on chronic kidney… read more here.
Keywords: disease; biological targeted; patients rheumatoid; group ... See more keywords
National rollout of a medication safety dashboard to improve testing for latent infections among biologic and targeted synthetic disease-modifying agent users within the Veterans Health Administration.
Sign Up to like & getrecommendations! Published in 2024 at "Health services research"
DOI: 10.1111/1475-6773.14363
Abstract: OBJECTIVE To develop, deploy, and evaluate a national, electronic health record (EHR)-based dashboard to support safe prescribing of biologic and targeted synthetic disease-modifying agents (b/tsDMARDs) in the United States Veterans Affairs Healthcare System (VA). DATA… read more here.
Keywords: dashboard; synthetic disease; disease modifying; biologic targeted ... See more keywords
POS1236 IMPACT OF COVID-19 ON INITIATION AND RENEWAL OF BIOTHERAPIES AND TARGETED SYNTHETIC TREATMENTS
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.3146
Abstract: During the epidemic’s peak of COVID-19, scientific societies published recommendations on biotherapy and targeted synthetic treatment (B/TST) use in patients with chronic articular inflammatory diseases, inflammatory bowel diseases, and psoriasis.The objective was to evaluate the… read more here.
Keywords: initiation renewal; initiation; tst; renewal ... See more keywords
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
Sign Up to like & getrecommendations! Published in 2023 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/ard-2022-223762
Abstract: Objective Longitudinal clinical registry-infrastructures such as Anti-Rheumatic Therapies in Sweden (ARTIS) allow simultaneous comparison of the safety of individual immunomodulatory drugs used in clinical practice, with consistent definitions of treatment cohorts, follow-up and outcomes. Our… read more here.
Keywords: safety; used clinical; disease; clinical practice ... See more keywords
Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.
Sign Up to like & getrecommendations! Published in 2023 at "PLoS computational biology"
DOI: 10.1371/journal.pcbi.1011073
Abstract: Cycling of biologic or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) in rheumatoid arthritis (RA) patients due to non-response is a problem preventing and delaying disease control. We aimed to assess and validate treatment response… read more here.
Keywords: biologic targeted; rheumatoid arthritis; deep learning; targeted synthetic ... See more keywords